{"id":80168,"date":"2026-06-09T14:23:15","date_gmt":"2026-06-09T14:23:15","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/80168\/"},"modified":"2026-06-09T14:23:15","modified_gmt":"2026-06-09T14:23:15","slug":"roche-eyes-covid-19-antibody-test-launch-in-may-the-guardian-nigeria-news","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/80168\/","title":{"rendered":"Roche eyes COVID-19 antibody test launch in May | The Guardian Nigeria News"},"content":{"rendered":"<p class=\"image-caption\">Logo on building exterior at the Silicon Valley[-]<br \/>\nheadquarters of pharmaceutical company Roche, Santa Clara, California, August 17, 2017. (Photo: Smith Collection\/Gado\/Getty Images<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-1144245\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/06\/images-13.jpeg\" alt=\"\" width=\"680\" height=\"451\"  \/>Logo on building exterior at the Silicon Valley[-]<br \/>headquarters of pharmaceutical company Roche, Santa Clara, California, August 17, 2017. (Photo: Smith Collection\/Gado\/Getty ImagesSwiss pharmaceutical giant Roche said Friday it had developed an antibody test that it hopes to roll out in May to detect people previously infected with COVID-19, even those who displayed no symptoms.\n<\/p>\n<p>Roche said in a statement that it had developed the Elecsys Anti-SARS-CoV-2 immunoassay, which using a blood sample can detect antibodies to determine the body\u2019s immune reaction to the novel coronavirus that causes COVID-19.\n<\/p>\n<p>Research teams around the world have been racing to develop such so-called serology tests for the virus, known as SARS-CoV-2, that has sparked the global pandemic with more than 2.1 million infections and over 141,000 deaths.<\/p>\n<p>\u201cAntibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms,\u201d the Roche statement pointed out.<\/p>\n<p>It added that such tests could also allow screening within high-risk groups like healthcare workers to determine if they may already have developed a certain level of immunity, Roche said.\n<\/p>\n<p>\u201cOnce we understand more about the immunity of COVID-19, it could also help society return faster to normality,\u201d it said.<\/p>\n<p>Roche said it was working with the US Food and Drug Administration (FDA) to ensure \u201cemergency use authorisation\u201d to bring its test to market, and said it would also be made available in markets that accept the European CE-mark certification.\n<\/p>\n<p>The company said it aimed to produce tens of millions of the new test by June and said it would subsequently \u201cfurther scale up production as fast as possible.\u201d<\/p>\n<p>Roche said the tests can be processed using multiple models of its analysers already in use in hospitals and reference laboratories around the world.<\/p>\n","protected":false},"excerpt":{"rendered":"Logo on building exterior at the Silicon Valley[-] headquarters of pharmaceutical company Roche, Santa Clara, California, August 17,&hellip;\n","protected":false},"author":2,"featured_media":80169,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[7233,14585,134],"class_list":["post-80168","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-coronavirus","tag-covid-19","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116720606071991671","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/80168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=80168"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/80168\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/80169"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=80168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=80168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=80168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}